Ticker: SVA, Company: SINOVAC BIOTECH LTD, Type: 6-K, Date: 2018-04-19
Original SEC Filing: Click here

---

Webplus: SVA/20180419/6-K/2_EX-99.1/000.htm SEC Original: tv491421_ex99-1.htm
Sinovac Announces Preliminary Results of Phase III Trial on sIPV BEIJING, April 19, 2018 — Sinovac Biotech Ltd. (NASDAQ: SVA) (“Sinovac ” or the “Company”), a leading provider of biopharmaceutical products in China, today announced preliminary results of a phase III clinical study on Sabin inactivated polio vaccine (“sIPV”) developed by Sinovac Biotech Co., Ltd. (“Sinovac Beijing”) on the unblinding

---

---

Webplus: SVA/20180419/6-K/1/000.htm SEC Original: tv491421_6k.htm

---

Company Info:

Ticker: SVA, Company: SINOVAC BIOTECH LTD, Type: 6-K, Date: 2018-04-19CIK: 0001084201, Location: F4, SIC: 2834, SIC Desc: PHARMACEUTICAL PREPARATIONS
Business Phone & Address:
39 SHANGDI XI ROAD, HAIDIAN DISTRICT
BEIJING 100085